Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Maxim -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (13)	2/2/2000 12:12:00 PM
From: biowa	Respond to of 24

Walter, MMP moves in spurts, they really need the analysts who (I assume) will come on board with the secondary. While not the steal that it was at $8 last fall, this still has most of its major news items ahead of it in 1H2000. Nice move on BPUR. biowa

To: WTDEC who wrote (13)	4/12/2000 3:09:00 PM
From: biowa	Read Replies (1) \| Respond to of 24

Walter, So what did you think of the 24-week HCV data? siliconinvestor.com Looked pretty good, and the call sounded very promising. What's more, during the call they kept using the phrase from the PR, "These results are consistent with the positive results we have seen when using Maxamine in other clinical studies for indications such as malignant melanoma..." They also seemed to take a very aggressive stance that they believe that Maxamine will be shown to be an effective adjuvant for "many" types of immunotherapy. Since the PIII malignant melanoma results are to be released at ASCO in May, can we assume that they already have them in hand (believe they said as much on the call, something about being analyzed)? Thus, their tone would suggest that they are positive. The company also said in response to a question that an NDA filing in July would be an appropriate guess. This is a bear market... biowa